Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha.
about
Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimizatiLong-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trCytogenetic clonal evolution alone in CML relapse post-transplantation does not adversely affect response to imatinib mesylate treatment.Once-daily dasatinib for treatment of patients with chronic myeloid leukemia.High-dose imatinib for newly diagnosed chronic phase chronic myeloid leukemia patients--systematic review and meta-analysis.Imatinib plasma trough concentration and its correlation with characteristics and response in Chinese CML patients.Significance of increasing levels of minimal residual disease in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in complete cytogenetic response.Measuring symptoms as a critical component of drug development and evaluation in hematological diseasesHigh-dose imatinib improves cytogenetic and molecular remissions in patients with pretreated Philadelphia-positive, BCR-ABL-positive chronic phase chronic myeloid leukemia: first results from the randomized CELSG phase III CML 11 "ISTAHIT" study.Efficacy of escalated imatinib combined with cytarabine in newly diagnosed patients with chronic myeloid leukemiaImmune modulation of minimal residual disease in early chronic phase chronic myelogenous leukemia: a randomized trial of frontline high-dose imatinib mesylate with or without pegylated interferon alpha-2b and granulocyte-macrophage colony-stimulatinLong-term prognostic impact of the use of erythropoietic-stimulating agents in patients with chronic myeloid leukemia in chronic phase treated with imatinibCurrent event-free survival after sequential tyrosine kinase inhibitor therapy for chronic myeloid leukemia.Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase.Cancer treatment with kinase inhibitors: what have we learnt from imatinib?The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemiaImatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance.Dasatinib: the emerging evidence of its potential in the treatment of chronic myeloid leukemia.Plasma exposure of imatinib and its correlation with clinical response in the Tyrosine Kinase Inhibitor Optimization and Selectivity Trial.Three-way complex variant translocation involving short arm chromosome (1;9;22)(p36;q34;q11) in a chronic myeloid leukemia patient.Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses and have lower failure rates than those randomized to standard-dose imatinib.The development and application of imatinib.Targeted therapy for hematologic malignancies.Personalized medical treatment strategies for patients with chronic myeloid leukemia.High-dose imatinib induction followed by standard-dose maintenance in pre-treated chronic phase chronic myeloid leukemia patients--final analysis of a randomized, multicenter, phase III trialTargeting the proteasome as a therapeutic strategy against haematological malignancies.Tipifarnib: farnesyl transferase inhibition at a crossroads.Analysis of 2013 European LeukaemiaNet (ELN) responses in chronic phase CML across four frontline TKI modalities and impact on clinical outcomes.Therapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec, Gleevectrade mark).Quantification of imatinib in human serum: validation of a high-performance liquid chromatography-mass spectrometry method for therapeutic drug monitoring and pharmacokinetic assays.Platelet-derived growth factor receptor as a prognostic marker and a therapeutic target for imatinib mesylate therapy in osteosarcoma.Molecular monitoring in chronic myeloid leukemia: response to tyrosine kinase inhibitors and prognostic implications.High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses.Tailoring tyrosine kinase inhibitor therapy in chronic myeloid leukemia.Higher dose imatinib for children with de novo chronic phase chronic myelogenous leukemia: a report from the Children's Oncology Group.NS-187 (INNO-406), a Bcr-Abl/Lyn dual tyrosine kinase inhibitor.Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapyState-of-the-art in the management of chronic myelogenous leukemia in the era of the tyrosine kinase inhibitors: evolutionary trends in diagnosis, monitoring and treatment.Biomarkers and the design of clinical trials in cancer.Optimizing the selection of kinase inhibitors for chronic myeloid leukemia patients.
P2860
Q30357011-820514D9-F203-46BC-B4C7-4AD836C15EEBQ31033077-65C1D0AB-6381-4DC1-AFDE-5D3D863D39FDQ33357697-FEB12C99-C416-45D5-8AC5-327CE8B2F4DFQ33383954-A4493302-FB8A-4B20-A0AB-DA92ADFD0DBCQ33396265-FF930E9D-8A0E-4D20-9FB6-CAA56208A303Q33557847-58CD2C93-A554-4B04-948E-A0B5FA0711FCQ33561232-67E944B5-72D9-48B5-A2E7-4BFE7976982FQ33705743-B942801B-E4B9-4F96-972E-598660D83D65Q33886162-E3278435-DF29-409B-B77B-EDD11E52A9B4Q33886167-D0E6B169-6295-45FC-B715-8E1C15E83E47Q35034528-B1DF172E-B1AA-47CE-B015-2551EC773225Q35073857-5A87009D-A1E4-424B-BD11-30BC3615E293Q35083184-71624A0C-38F8-4AE3-9EDB-4B1D5F3372E5Q35300745-370BBF6F-7507-4E52-AFAA-3F3A114E8016Q35622440-6B5AE94B-DA77-4988-87A6-21D559EB0174Q35628978-172B32CF-924A-4108-B068-9868CA0CE1E2Q35816396-5B924A8C-8410-4F42-B61F-AA0DF4403669Q35876347-785FC2BC-D49D-4B31-8C87-41F88FF14257Q35930616-193258DB-88E2-49C1-BCEC-6E5EC421EF85Q35944604-5E20C0BD-FDCC-486E-A5BB-840143080824Q36006408-215EAEFA-D502-4EED-8B75-4949E605A37FQ36081983-E3D6B2F5-675E-4139-B602-822AA5F0A357Q36108610-D18D37FA-BEB2-4800-9FC4-3474716086C1Q36118424-D2E37041-7D0B-48A0-A28A-6C8C0715FC88Q36366958-A41D94F9-F89A-4AD0-B80E-DE15A3507A7EQ36376437-3AC83FDA-6678-49BF-A0C5-42C725D8C070Q36407429-69BE06C0-4905-4A33-84CC-4235A9D10FBCQ36734508-EA073D54-4179-4D1E-941B-98A9BA4CD7F3Q36822880-986A532E-9AD1-43A4-9EAB-82567BCFC933Q37085189-9F6D7856-4BCF-4F41-BBDA-A93E5CC62C9CQ37109503-4631CA25-10DD-494C-BB58-C98567438BFDQ37112773-01F16396-5AFC-4398-B5CC-32EFBA0EC9D7Q37163734-B161178D-E8C0-45AE-A240-A8C37E95620AQ37428659-DC3F3326-507B-4EE5-8A7B-33BAE2883071Q37505017-E25E4DC7-8B5A-419D-97F7-2DAAF0F81038Q37574957-E2A3C5CD-50CE-4568-8640-CC2D21FAEB54Q37635598-59F1B7E2-2CDE-44DB-B8EB-CE94B3546A1EQ37657478-28136F4C-22B0-4CE5-BC1B-FA921CE28CFBQ37755081-82F7BF0C-B3B4-4BA4-9727-E533C0C73B43Q37888714-B3E017F5-4067-401E-AB2C-F354B0C39E73
P2860
Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Result of high-dose imatinib m ...... r failure of interferon-alpha.
@en
Result of high-dose imatinib m ...... r failure of interferon-alpha.
@nl
type
label
Result of high-dose imatinib m ...... r failure of interferon-alpha.
@en
Result of high-dose imatinib m ...... r failure of interferon-alpha.
@nl
prefLabel
Result of high-dose imatinib m ...... r failure of interferon-alpha.
@en
Result of high-dose imatinib m ...... r failure of interferon-alpha.
@nl
P2093
P50
P1433
P1476
Result of high-dose imatinib m ...... r failure of interferon-alpha.
@en
P2093
Deborah Thomas
Emil J Freireich
Moshe Talpaz
P356
10.1182/BLOOD-2003-01-0025
P407
P50
P577
2003-03-13T00:00:00Z